atai life science stock

Atai Life Sciences listed on Nasdaq for its IPO on June 18, 2021.Source: NasdaqAtai Life Sciences, the Peter Thiel-supported start-up that aims to use psychedelic drugs to treat mental illness, has increased its stake in the drug developer Compass Pathways.Atai bought an additional 420,000 Compass Pathways shares in C. CITIGROUP INC. 71.37. atai Life Sciences Increases its Ownership Position in ... Atai has added to its ownership stake in COMPASS, elevating its ownership interest from slightly more than 19% to nearly 21%. Articles. atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update. atai Life Sciences Increases its Ownership Position in ... ATAI Life Sciences Successfully Closes $43 Million Series ... Over the short-term, Psychedelic Stock Watch sees the best investment opportunities from this IPO in other psychedelic stocks. atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update. How to buy atai Life Sciences stock on Stash. The company was founded by Christian Angermayer . ATAI Life Sciences AG operates as a biotech company. The current stock price of Atai Life Sciences is $15.93. ATAI Life Sciences NV. NEW YORK, Nov. 23, 2020 /PRNewswire/ -- ATAI Life Sciences (" ATAI" or the " Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. ATAI Life Sciences is poised to become the new industry leader among public companies when it commences trading as a new psychedelic stock. Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass . The company plans to offer 14.3 million shares and has set the pricing range at $13-$15 . Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101 . Atai Life Sciences, which supports psychedelic drug developers seeking new ways to treat mental illness, hopes to raise $100 million in an initial public offering. Their forecasts range from $17.00 to $45.00. Atai Life Sciences is a clinical-stage biopharma business striving to change the way in which mental health disorders are treated. Atai Life Sciences' IPO news. These 6 analysts have an average price target of $31.33 versus the current price of ATAI Life Sciences at $10.6915, implying upside. Atai Life Sciences is a clinical-stage biopharma business striving to change the way in which mental health disorders are treated. Once again, this major announcement can be expected to be an important sector catalyst. Day's Range: $12.38 - $15.12. ATAI is pioneering the development of more effective and potentially-disease modifying mental health treatments for patients' suffering from significant unmet medical needs. Wall Street Stock Market & Finance report, prediction for the future: You'll find the ATAI Life Sciences N.V. share forecasts, stock quote and buy / sell signals below.According to present data ATAI Life Sciences N.V.'s ATAI shares and potentially its market environment have been in a . Now ATAI Life Sciences has announced it is going public in early 2021. This suggests a possible upside of 150.3% from the stock's current price. ATAI Life Sciences market cap is $2.3 b.. View ATAI Life Sciences stock / share price, financial statements, key ratios and more at Craft. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. 's earnings in 2021 is N/A.. On average, 4 Wall Street analysts forecast ATAI's earnings for 2021 to be $-143,982,392, with the lowest ATAI earnings forecast at $-218,295,884, and the highest ATAI earnings forecast at $-86,699,075. Atai Life Sciences. It's no secret to investors in psychedelic stocks that ATAI Life Sciences will be filing for a NASDAQ IPO early in 2021. ATAI Life Sciences Successfully Closes $43 Million Series B Financing Round. Atai Lifesciences has filed for the IPO and is expected to list on June 18. Below is a summary of how these 6 analysts rated ATAI Life . ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. At a more than $2 billion valuation, atai will have the highest market cap of all pureplay psychedelic companies currently on the market. You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes included in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2020, included in our prospectus dated June 17, 2021 (the "Prospectus"), as . ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI Life Sciences has raised a total of $347.1M in funding over 9 rounds. Last Funding Type Series D. Also Known As ATAI, ATAI Life Sciences. Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pat BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. Founded in 2018, ATAI Life Sciences is a biotechnology company headquartered in Berlin. Once atai Life Sciences goes public, investors would be able to invest in its stock via a brokerage account. Atai Life Sciences (), a backer of psychedelic-drug developers, began trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of . SAINT LAURENT, Quebec, and NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp . NEW YORK & LONDON & BERLIN-- ( BUSINESS WIRE )--ATAI Life Sciences, the global biotech platform dedicated to curing . Presented as part of the CSE and CFN Media's exclusive video series on Investing in Psychedelics. NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on . A platform for innovation and accelerating mental healthcare solutions. About ATAI. Continued progress across 11 therapeutic research programs. View atai Life Sciences N.V. ATAI investment & stock information. Below is a summary of how these 6 analysts rated ATAI Life . Its last market close was $16.4 - a decrease of 21.92% over the previous week. 2. atai does not provide operational support to COMPASS Pathways. All common shares to be sold in the proposed offering will be sold by atai. TradingView Medium Chart Widget. Atai Life Sciences N.V. (NASDAQ:ATAI) went up by 8.30% from its latest closing price compared to the recent 1-year high of $22.91. Legal Name ATAI Life Sciences AG. ATAI Life Sciences N.V. () Stock Market info Recommendations: Buy or sell ATAI Life Sciences N.V. stock? Use our comparison table to help you find a platform that fits you. Investor Type Corporate Venture Capital. atai Life Sciences reports its Q3 2021 financial results. Over the short-term, Psychedelic Stock Watch sees the best investment opportunities from this IPO in other psychedelic stocks. Actively observing the price movement in the last trading, the stock closed the session at $11.31 Source: Nasdaq. Key Data Points. The Cannabis Investor is a leading social media outlet for Cannabis investment opportunities and breaking industry news. A look at the daily price movement shows that the last close reads $14.92, with intraday deals fluctuated between $12.38 and $15.115. ATAI Life Sciences is poised to become the new industry leader among public companies when it commences trading as a new psychedelic stock. Volume has increased on the last day by 173 thousand shares but on falling prices. IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive. The company's stock price has collected 3.15% of gains in the last five trading sessions. ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Today ATAI stock price opened at $16.93 after previous close of $16.60. This interview with ATAI Life Sciences' Aaron Weaver highli. Below is a summary of how these 6 analysts rated ATAI Life . Can You Buy ATAI Stock? ATAI is planning to offer their shares to the public in an IPO that expects to raise $100 million. Compare share trading platforms. That news came out when ATAI recently completed its Series C financing round - raising $125 million. +0.86 +1.22%. ATAI Life Sciences is a private biopharmaceutical company that was founded in 2018. The company seeks to develop effective mental health treatments by researching both psychedelic and non-psychedelic compounds. A high-level overview of Atai Life Sciences N.V. (ATAI) stock. Atai Life Sciences Share Price and News. and has now fallen 5 days in a row.During the day the stock fluctuated 12.61% from a day low at $10.94 to a day high of $12.32.The price has fallen in 9 of the last 10 days and is down by -36.74% for this period. Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass . Current Price: $13.18. Their latest funding was raised on Mar 3, 2021 from a Series D round. ATAI Life Sciences is in pursuit of finding reasonable and natural cures and treatments for mental health issues. Since ATAI Life Sciences' ( NASDAQ:ATAI) outsize initial public offering (IPO) on June 22, it's flush with an estimated $225 million in cash. RL-007 is a proprietary, orally available small molecule (GABA / nicotinic modulator). Founders Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao. NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders . ATAI Life Sciences is registered under the ticker NASDAQ:ATAI . These 6 analysts have an average price target of $31.33 versus the current price of ATAI Life Sciences at $10.6915, implying upside. Primary metrics and data points about Atai Life Sciences N.V.. Market Cap: $2B. It is based in Berlin, Germany. Atai Life Sciences employs 35 staff and has a trailing 12-month revenue of around $19.9 million. The historical data and Price History for Atai Life Sciences N.V. (ATAI) with Intraday, Daily, Weekly, Monthly, and Quarterly data available for download. View the latest ATAI stock quote and chart on MSN Money. Once Atai Life Sciences goes public, you'll need a brokerage account to invest. The ATA Inc. stock price fell by -7.70% on the last day (Thursday, 18th Nov 2021) from $12.20 to $11.26. Find the latest ATAI Life Sciences N.V. (ATAI) stock quote, history, news and other vital information to help you with your stock trading and investing. How to buy shares in Atai Life Sciences when it goes public. Founded in 2018, ATAI Life Sciences is a German biotech startup that has raised $304 million in disclosed funding to build a holding company that creates, invests in, or acquires businesses developing psychedelic therapies.

Athletic Fit Dress Shirts, A Simple Plan Film Analysis, Russian Mansions For Sale, Anticipation Definition, Singapore University Of Technology And Design Scholarship, European Court Of Human Rights, Kamala Bose Vanu Bose, Led Triggered Drum Lights, Covid Recovery Certificate, Pinnacles National Park Map, I Like The Way You Comb Your Hair Remix,